Atlas Venture Life Science Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-76,979	Closed	-$2.11M	–	14
2024 Q3	$2.11M	Sell	76,979 -60,000	-44%	-$1.67M	0.2%	13
2024 Q2	$3.55M	Sell	136,979 -50,000	-27%	-$1.2M	0.37%	13
2024 Q1	$5.61M	Sell	186,979 -50,000	-21%	-$1.09M	0.52%	14
2023 Q4	$2.46M	Hold	236,979	–	–	0.29%	14
2023 Q3	$3.24M	Sell	236,979 -2	-0%	-$25	0.5%	14
2023 Q2	$2.87M	Hold	236,981	–	–	0.36%	14
2023 Q1	$3.01M	Buy	236,981 +19,697	+9%	+$218K	0.41%	14
2022 Q4	$1.37M	Hold	217,284	–	–	0.17%	17
2022 Q3	$4.9M	Hold	217,284	–	–	0.54%	13
2022 Q2	$4.17M	Hold	217,284	–	–	0.7%	12
2022 Q1	$10.1M	Hold	217,284	–	–	1.27%	11
2021 Q4	$15.4M	Buy	+217,284	New	+$21.8M	1.41%	12

Other funds holding DNTH

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return